ストックスクリーナーアプリを入手
31.53
2.40%
0.74
前日終値:
$30.79
開ける：
$31.52
24時間の取引高:
308.93K
Relative Volume:
1.95
時価総額：
$498.23M
収益：
$925.00K
当期純損益:
$-98.64M
株価収益率:
-6.282
EPS:
-5.0191
ネットキャッシュフロー:
$-83.37M
1週間 パフォーマンス:
+8.72%
1か月 パフォーマンス:
+12.69%
6か月 パフォーマンス:
+63.54%
1年 パフォーマンス:
+72.30%
1日の値動き範囲:
$31.03
$32.50
1週間の範囲:
$28.20
$32.50
52週間の値動き範囲:
$14.65
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
31.53 | 498.23M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Craig Hallum | Buy |
| 2025-05-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2024-03-21 | 開始されました | William Blair | Outperform |
| 2024-01-08 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-05 | 開始されました | Stifel | Buy |
| 2024-01-04 | 開始されました | TD Cowen | Outperform |
すべてを表示
Neurogene Inc (NGNE) 最新ニュース
Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurogene Inc (NGNE) Institutional Confidence - TradingKey
Neurogene Inc (NGNE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurogene Inc (NGNE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurogene Inc (NGNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurogene Inc (NGNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurogene Inc (NGNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neurogene Inc (NGNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurogene Inc (NGNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dosing of Rett gene therapy NGN-401 complete in Embolden study - Rett Syndrome News
Neurogene (NGNE) director receives stock option grant for 15,400 shares - Stock Titan
Neurogene (NGNE) director receives fully vested grant of 7,700 stock options - Stock Titan
Neurogene (NGNE) director receives 12,050 fully vested stock options at $20.40 - Stock Titan
Neurogene (NGNE) director Woods Keith submits amended Form 3 ownership - Stock Titan
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Inc. (NGNE) Holds Steady Near Resistance as Biotech Sector WatchesBreakaway Gap - newsline.com
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE) - The Globe and Mail
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues R&D InvestmentEPS Surprise History - newsline.com
NGNE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $70 - GuruFocus
Neurogene stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
NGNE Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress ContinuesGAAP Earnings Report - newsline.com
Neurogene (NGNE) Completes Dosing in Key Trial for NGN-401 - GuruFocus
Number of shareholders of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene Completes Dosing in Pivotal Embolden™ Trial of NGN-401 Gene Therapy for Rett Syndrome - Minichart
Neurogene Completes Dosing in Embolden Rett Trial - TipRanks
Neurogene completes dosing in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
Neurogene completes dosing in Embolden trial, doses 25 participants; topline data due 2H 2027 - TradingView
Neurogene Inc. finalizes administration phase in pivotal Embolden study - Traders Union
Neurogene completes dosing in Rett syndrome gene therapy trial - Investing.com
Neurogene (NGNE) finishes dosing in NGN-401 Embolden Rett registrational trial - Stock Titan
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome - The Joplin Globe
25 girls receive Neurogene’s one-time gene therapy in key Rett syndrome trial - Stock Titan
NEUROGENE INC (NGNE) Stock Chart - ChartMill
Neurogene Inc. Files Form 8-K with SEC Detailing Corporate Information and NASDAQ Listing - Minichart
Neurogene Stockholders Vote on Directors and Executive Pay - TipRanks
Neurogene (NGNE) investors back board slate, pay plan and auditor - Stock Titan
NGNE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rodman & Renshaw initiates Neurogene stock with buy on gene therapy - Investing.com Nigeria
Two new Neurogene hires get options on 17,045 company shares - Stock Titan
Neurogene Inc. (NGNE) Gains 3% as Biotech Sentiment Lifts SharesWeak Sell Signals - newsline.com
Neurogene Inc. (NGNE) Rallies 3.05% as Technical Support Holds Above $27Analyst Downgrade Signals - newsline.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
Neurogene’s Stock Run Is Riding A Rett Gene Therapy Bet - Finimize
Neurogene Inc. (NGNE) Shows Resilience: Gains 2.45% as Biotech Sector Looks to ReboundCrowd Entry Signals - newser.com
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear - Bez Kabli
Neurogene (NGNE) Q1 2026 Results Miss Estimates — EPS $-1.39 vs $-1.32Slow Growth Warning - Newser
NGNE News | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
Neurogene Inc (NGNE) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):